| Autor: |
Etsuko Yokota, Miki Iwai, Takuro Yukawa, Masakazu Yoshida, Yoshio Naomoto, Minoru Haisa, Yasumasa Monobe, Nagio Takigawa, Minzhe Guo, Yutaka Maeda, Takuya Fukazawa, Tomoki Yamatsuji |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2397-768X |
| DOI: |
10.1038/s41698-021-00166-3 |
| Popis: |
Abstract Despite high expectations for lung tumoroids, they have not been applied in the clinic due to the difficulty of their long-term culture. Here, however, using AO (airway organoid) media developed by the Clevers laboratory, we succeeded in generating 3 lung tumoroid lines for long-term culture (>13 months) from 41 lung cancer cases (primary or metastatic). Use of nutlin-3a was key to selecting lung tumoroids that harbor mutant p53 in order to eliminate normal lung epithelial organoids. Next-generation sequencing (NGS) analysis indicated that each lung tumoroid carried BRAF G469A , TPM3-ROS1 or EGFR L858R /RB1 E737* , respectively. Targeted therapies using small molecule drugs (trametinib/erlotinib for BRAF G469A , crizotinib/entrectinib for TPM3-ROS1 and ABT-263/YM-155 for EGFR L858R /RB1 E737* ) significantly suppressed the growth of each lung tumoroid line. AO media was superior to 3 different media developed by other laboratories. Our experience indicates that long-term lung tumoroid culture is feasible, allowing us to identify NGS-based therapeutic targets and determine the responsiveness to corresponding small molecule drugs. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
